Advertisement

Neurourology pp 401-408 | Cite as

Other New Developments: Use of Stem Cells and Gene Therapy

  • Karl-Dietrich SievertEmail author
  • M. Renninger
  • C. Füllhase
Chapter

Abstract

Stem cell and gene therapies are progressively entering clinical reality and have the potential to revolutionize medicine. According to the United States National Marrow Donor Program (NMDP), the world’s largest hematopoietic cell registry several blood cancers can be successfully treated using blood stem cell transplantation. The invention of induced pluripotent stem cell (iPSC) technology is one of the main landmarks of stem cell medicine. The Nobel Prize awarded gene-therapy, the therapeutic delivery of nucleic acids into a patient’s cell to treat a disease, is considered another gamechanging technology in medicine and future clinical practice. Despite the enthusiastic situation surrounding stem cell research and gene therapy, both technologies have not yet really succeeded into functional urology—at least on a translational level. The only relevant stem cell applications in functional urological diseases that have been introduced so far have been in incontinence and erectile dysfunction (ED) area, however, no clinical trials using either stem cells or gene therapy have been initiated in patients with neurogenic bladder. Therefore, the following article will focus on stem cell sources and discuss pre-clinical and clinical data in stem cell and gene therapy in erectile dysfunction and incontinence.

References

  1. 1.
    Mimeault M, Hauke R, Batra SK. Stem cells: a revolution in therapeutics-recent advances in stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin Pharmacol Ther. 2007;82:252–64.PubMedCrossRefGoogle Scholar
  2. 2.
    National Marrow Donor Program. Diseases treatable by transplants. https://bethematch.org. Accessed Aug 2017.
  3. 3.
    Majhail NS, Farnia SH, Carpenter PA. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1863–9.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Worldwide Network For Blood & Marrow Transplantation, One million transplants. www.wbmt.org. Accessed Aug 2017.
  5. 5.
    Barfoot J. Stem cell research: trends and perspectives on the evolving international landscape. https://www.elsevier.com/research-intelligence/resource-library/stem-cell-research-trends-and-perspectives-on-the-evolving-international-landscape. Accessed Aug 2017.
  6. 6.
    National Library of Medicine. Search terms: intervention: “stem cells”, limits: “study phase II or III” and “recruiting”. https://clinicaltrials.gov. Accessed Aug 2017.
  7. 7.
    Weiss MJ, Mullighan CG. Welcoming a new age for gene therapy in hematology. Blood. 2016;127:2523–4.PubMedCrossRefGoogle Scholar
  8. 8.
    National Library of Medicine. Search terms: intervention: “gene therapy”, limits: “study phase II or III” and “recruiting”. https://clinicaltrials.gov. Accessed Aug 2017.
  9. 9.
    Kim JH, Lee HJ, Song YS. Treatment of bladder dysfunction using stem cell or tissue engineering technique. Korean J Urol. 2014;55:228–38.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441:1094–6.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Cote DJ, Bredenoord AL, Smith TR, et al. Ethical clinical translation of stem cell interventions for neurologic disease. Neurology. 2017;88:322–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Simonato M, Bennett J, Boulis NM, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013;9:277–91.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Chan YY, Sandlin SK, Kurzrock EA, et al. The current use of stem cells in bladder tissue regeneration and bioengineering. Biomedicine. 2017;5:E4.CrossRefGoogle Scholar
  14. 14.
    Bongso A, Fong CY, Gauthaman K. Taking stem cells to the clinic: major challenges. J Cell Biochem. 2008;105:1352–60.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Choumerianou DM, Dimitriou H, Kalmanti M. Stem cells: promises versus limitations. Tissue Eng Part B Rev. 2008;14:53–60.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Renninger M, Amend B, Seibold J, et al. Chapter 16: Regeneration of the lower urinary tract: clinical applications an future outlook. In: Gorodetsky R, Schäfer R, editors. Stem cell-based tissue repair. London: The Royal Society of Chemistry; 2011. p. 324–45.Google Scholar
  17. 17.
    Shokeir AA, Harraz AM, El-Din AB, et al. Tissue engineering and stem cells: basic principles and applications in urology. Int J Urol. 2010;17:964–73.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Sievert KD, Amend B, Stenzl A. Tissue engineering for the lower urinary tract: a review of a state of the art approach. Eur Urol. 2007;52:1580–9.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Chamberlain G, Fox J, Ashton B, et al. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–49.PubMedCrossRefGoogle Scholar
  20. 20.
    Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Furuta A, Carr LK, Yoshimura N, et al. Advances in the understanding of sress urinary incontinence and the promise of stem-cell therapy. Rev Urol. 2007;9:106–12.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211–28.PubMedCrossRefGoogle Scholar
  24. 24.
    Lin CS, Xin ZC, Deng CH, et al. Histol Histopathol. 2010;25:807–15.PubMedGoogle Scholar
  25. 25.
    Izadyar F, Wong J, Maki C, et al. Identification and characterization of repopulating spermatogonial stem cells from the adult human testis. Hum Reprod. 2011;26:1296–306.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Atala A. Tissue engineering of human bladder. Br Med Bull. 2011;97:81–104.PubMedCrossRefGoogle Scholar
  27. 27.
    Fu Q, Song XF, Liao GL, et al. Myoblasts differentiated from adipose-derived stem cells to treat stress urinary incontinence. Urology. 2010;75:718–23.PubMedCrossRefGoogle Scholar
  28. 28.
    Sharma AK, Fuller NJ, Sullivan RR, et al. Defined populations of bone marrow derived mesenchymal stem and endothelial progenitor cells for bladder regeneration. J Urol. 2009;182:1898–905.PubMedCrossRefGoogle Scholar
  29. 29.
    Drost AC, Weng S, Feil G, et al. In vitro myogenic differentiation of human bone marrow-derived mesenchymal stem cells as a potential treatment for urethral sphincter muscle repair. Ann N Y Acad Sci. 2009;1176:135–43.PubMedCrossRefGoogle Scholar
  30. 30.
    Liu J, Huang J. Cell-to-cell contact induces human adipose tissue-derived stromal cells to differentiate into urothelium-like cells in vitro. Biochem Biophys Res Commun. 2009;390:931–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Ning H, Gang LM, Lin G, et al. Fibroblast growth factor 2 promotes endothelial differentiation of adipose tissue-derived stem cells. J Sex Med. 2009;6:967–79.PubMedCrossRefGoogle Scholar
  32. 32.
    Vaegler M, Schenke-Layland K, Stenzla A, et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472:110–4.CrossRefGoogle Scholar
  33. 33.
    Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.PubMedCrossRefGoogle Scholar
  34. 34.
    Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448:318–24.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Okita K, Nakagawa M, Hong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322:949–53.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Damaser MS, Sievert KD. Tissue engineering and regenerative medicine: bench to bedside in urology. Preface. Adv Drug Deliv Rev. 2015;82–83:v–vii.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Yiou R, Yoo JJ, Atala A. Restoration of functional motor units in a rat model of sphincter injury by muscle precursor cell autografts. Transplantation. 2003;76:1053–60.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Cannon TW, Ji YL, Somogyi G, et al. Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology. 2003;62:958–63.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Alwaal A, Hussein AA, Lin CS, et al. Prospects of stem cell treatment in benign urological diseases. Korean J Urol. 2015;56:257–65.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Badra S, Andersson KE, Dean A, et al. Long-term structural and functional effects of autologous muscle precursor cell therapy in a nonhuman primate model of urinary sphincter deficiency. J Urol. 2013;190:1938–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Kim JH, Song YS. Current status of stem cell therapy in urology. Korean J Urol. 2015;56:409–11.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. 2014;192:469–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Sievert KD, Amend B, Renninger M, et al. Value of stem cell therapy for the treatment of stress incontinence. Current status and perspectives. Urologe A. 2007;46:264–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Mitterberger M, et al. Improment of urethral closure pressures after application of myoblasts depends on the number of injected cells. Eur Urol Suppl. 2006;5:p40.CrossRefGoogle Scholar
  45. 45.
    Kajbafzadeh AM, Elmi A, Payabvash S, et al. Transurethral autologous myoblast injection for treatment of urinary incontinence in children with classic bladder exstrophy. J Urol. 2008;180:1098–105.PubMedCrossRefGoogle Scholar
  46. 46.
    Kim SO, Na HS, Kwon D, et al. Bone-marrow-derived mesenchymal stem cell transplantation enhances closing pressure and leak point pressure in a female urinary incontinence rat model. Urol Int. 2011;86:110–6.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Corcos J, Loutochin O, Campeau L, Eliopoulos N, Bouchentouf M, Blok B, Galipeau J. Bone marrow mesenchymal stromal cell therapy for external urethral sphincter restoration in a ratmodel of stress urinary incontinence. Neurourol Urodyn. 2011;30(3):447–55.  https://doi.org/10.1002/nau.20998. PMID: 21412824.CrossRefPubMedGoogle Scholar
  48. 48.
    Lee JY, Paik SY, Yuk SH, et al. Long term effects of muscle-derived stem cells on leak point pressure and closing pressure in rats with transected pudendal nerves. Mol Cells. 2004;18:309–13.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Lee JY, Cannon TW, Pruchnic R, et al. The effects of periurethral muscle-derived stem cell injection on leak point pressure in a rat model of stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:31–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Chermansky CJ, Tarin T, Kwon DD, et al. Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. Urology. 2004;63:780–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Kim KH, Lee HS, Kim TB. Does transplantation of adipose tissue-derived stem cells have effects on micturition center in stress urinary incontinence?: in vivo animal study. J Urol. 2009;181:44.CrossRefGoogle Scholar
  52. 52.
    Lin G, Wang G, Banie L, et al. Treatment of stress urinary incontinence with adipose tissue-derived stem cells. Cytotherapy. 2010;12:88–95.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Zhao W, Zhang C, Jin C, et al. Periurethral injection of autologous adipose-derived stem cells with controlled-release nerve growth factor for the treatment of stress urinary incontinence in a rat model. Eur Urol. 2011;59:155–63.PubMedCrossRefGoogle Scholar
  54. 54.
    Kinebuchi Y, Aizawa N, Imamura T, et al. Autologous bone-marrow-derived mesenchymal stem cell transplantation into injured rat urethral sphincter. Int J Urol. 2010;17:359–68.PubMedCrossRefGoogle Scholar
  55. 55.
    Tamaki T, Uchiyama Y, Okada Y, et al. Functional recovery of damaged skeletal muscle through synchronized vasculogenesis, myogenesis, and neurogenesis by muscle-derived stem cells. Circulation. 2005;112:2857–66.PubMedCrossRefGoogle Scholar
  56. 56.
    Kwon D, Kim Y, Pruchnic R, et al. Periurethral cellular injection: comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. Urology. 2006;68:449–54.PubMedCrossRefGoogle Scholar
  57. 57.
    Carr LK, Steele D, Steele S, et al. 1-year follow-up of autologous muscle-derived stem cell injection pilot study to treat stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19:881–3.PubMedCrossRefGoogle Scholar
  58. 58.
    Yamamoto T, Gotoh M, Hattori R, et al. Periurethral injection of autologous adipose-derived stem cells for the treatment of stress urinary incontinence in patients undergoing radical prostatectomy: report of two initial cases. Int J Urol. 2010;17:75–82.PubMedCrossRefGoogle Scholar
  59. 59.
    Gotoh M, Yamamoto T, Kato M, et al. Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients. Int J Urol. 2014;21:294–300.PubMedCrossRefGoogle Scholar
  60. 60.
    Albersen M, Fandel TM, Lin G, et al. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med. 2010;7:3331–40.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Kendirci M, Trost L, Bakondi B, et al. Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. J Urol. 2010;184:1560–6.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H1278–90.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Qiu X, Sun C, Yu W, et al. Combined strategy of mesenchymal stem cells injection with VEGF gene therapy for the treatment of diabetes associated erectile dysfunction. J Androl. 2012;33:37–44.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Zhang HY, Jin XB, Lue TF. Three important components in the regeneration of the cavernous nerve: brain-derived neurotrophic factor, vascular endothelial growth factor and the JAK/STAT signaling pathway. Asian J Androl. 2011;13:231–5.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Lin CS, Ho HC, Chen KC, et al. Intracavernosal injection of vascular endothelial growth factor induces nitric oxide synthase isoforms. BJU Int. 2002;89:955–60.PubMedCrossRefGoogle Scholar
  66. 66.
    Lin G, Shindel AW, Fandel TM, et al. Neurotrophic effects of brain-derived neurotrophic factor and vascular endothelial growth factor in major pelvic ganglia of young and aged rats. BJU Int. 2010;105:114–20.PubMedCrossRefGoogle Scholar
  67. 67.
    Qiu X, Villalta J, Ferretti L, et al. Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction. J Sex Med. 2012;9:1834–41.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Bahk JY, Jung JH, Han H, et al. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant. 2010;8:150–60.PubMedGoogle Scholar
  69. 69.
    Soebadi MA, Milenkovic U, Weyne E, et al. Stem cells in male sexual dysfunction: are we getting somewhere? Sex Med Rev. 2017;5:222–35.PubMedCrossRefGoogle Scholar
  70. 70.
    Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016;5:204–10.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Yiou R, Hamidou L, Birebent B, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2016;69:988–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006;17:1165–76.PubMedCrossRefGoogle Scholar
  73. 73.
    Christ GJ, Andersson KE, Williams K, et al. Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol. 2009;56:1055–66.PubMedCrossRefGoogle Scholar
  74. 74.
    Nitta M, Tamaki T, Tono K, et al. Reconstitution of experimental neurogenic bladder dysfunction using skeletal muscle-derived multipotent stem cells. Transplantation. 2010;89:1043–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Liang CC, Lee TH, Chang SD. Effect of umbilical cord blood stem cells transplantation on bladder dysfunction induced by cerebral ischemia in rats. Taiwan J Obstet Gynecol. 2016;55:672–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Soler R, Füllhase C, Santos C, et al. Development of bladder dysfunction in a rat model of dopaminergic brain lesion. Neurourol Urodyn. 2011;30:188–93.PubMedCrossRefGoogle Scholar
  77. 77.
    Soler R, Füllhase C, Hanson A, et al. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol. 2012;187:1491–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Lee HJ, Won JH, Doo SH, et al. Inhibition of collagen deposit in obstructed rat bladder outlet by transplantation of superparamagnetic iron oxide-labeled human mesenchymal stem cells as monitored by molecular magnetic resonance imaging (MRI). Cell Transplant. 2012;21:959–70.PubMedCrossRefGoogle Scholar
  79. 79.
    Song YS, Lee HJ, Doo SH, et al. Mesenchymal stem cells overexpressing hepatocyte growth factor (HGF) inhibit collagen deposit and improve bladder function in rat model of bladder outlet obstruction. Cell Transplant. 2012;21:1641–50.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Woo LL, Tanaka ST, Anumanthan G, et al. Mesenchymal stem cell recruitment and improved bladder function after bladder outlet obstruction: preliminary data. J Urol. 2011;185:1132–8.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Song M, Heo J, Chun JY, et al. The paracrine effects of mesenchymal stem cells stimulate the regeneration capacity of endogenous stem cells in the repair of a bladder-outlet-obstruction-induced overactive bladder. Stem Cells Dev. 2014;23:654–63.PubMedCrossRefGoogle Scholar
  82. 82.
    Chen S, Zhang HY, Zhang N, et al. Treatment for chronic ischaemia-induced bladder detrusor dysfunction using bone marrow mesenchymal stem cells: an experimental study. Int J Mol Med. 2012;29:416–22.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Huang YC, Shindel AW, Ning H, et al. Adipose derived stem cells ameliorate hyperlipidemia associated detrusor overactivity in a rat model. J Urol. 2010;183:1232–40.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Zhang H, Qiu X, Shindel AW, et al. Adipose tissue-derived stem cells ameliorate diabetic bladder dysfunction in a type II diabetic rat model. Stem Cells Dev. 2012;21:1391–400.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Goins WF, Yoshimura N, Phelan MW, et al. Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction. J Urol. 2001;165:1748–54.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Miyazato M, Sugaya K, Goins WF, et al. Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther. 2009;16:660–8.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Hodges SJ, Yoo JJ, Mishra N, Atala A. The effect of epigenetic therapy on congenital neurogenic bladders—a pilot study. Urology. 2010;75:868–72.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Karl-Dietrich Sievert
    • 1
    • 2
    • 3
    Email author
  • M. Renninger
    • 2
  • C. Füllhase
    • 4
  1. 1.Klinik für Urologie, Section NeuroUrology and Reconstructive UrologyKlinikum LippeDetmoldGermany
  2. 2.Department of UrologyUniversity Hospital Tübingen (UKT)TübingenGermany
  3. 3.Department of UrologyMedical University ViennaViennaAustria
  4. 4.Department of UrologyUniversity Hospital of the SaarlandHomburg/SaarGermany

Personalised recommendations